Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Åke Lernmark

Principal investigator

Default user image.

Autoimmune type 1 diabetes.

Author

  • Ahmed Delli
  • Helena Larsson
  • Sten Ivarsson
  • Åke Lernmark

Editor

  • Richard I. G. Holt
  • Clive S. Cockram
  • Allan Flyvbjerg
  • Barry J. Goldstein

Summary, in English

The pathophysiologic mechanisms in type 1 diabetes (T1DM) involve loss of islet β-cell secretory function caused by selective killing of these

cells primarily by aggressive autoimmune responses involving both cellular and humoral immune pathways. Inflammatory cells heavily infiltrate pancreatic islets leading to insulitis where CD8+ T lymphocytes are thought to be responsible for selective and specific killing of β-cells.

The complex etiology of T1DM involves a strong genetic predisposition, mainly human leukocyte antigen class II genes, and several putative

environmental factors, which are thought to trigger autoimmunity or progression to clinical T1DM.

A preclinical prodrome in T1DM may vary in duration in which one or more islet autoantibodies may precede insulitis and predict the disease

at the early stages of pathologic insult. In genetically susceptible individuals with islet autoantibodies, metabolic indicators such as insulin release abnormalities and insulin resistance may best predict T1DM especially near clinical onset.

Based on the improving understanding of the etiopathogenesis of T1DM, several clinical trials have been launched aiming at halting the

autoimmunity responses, retarding disease progression or preserving remaining β-cell function after clinical onset.

Department/s

  • Diabetes and Celiac Unit
  • Paediatric Endocrinology
  • EXODIAB: Excellence in Diabetes Research in Sweden

Publishing year

2010

Language

English

Pages

141-152

Publication/Series

Textbook of Diabetes

Document type

Book chapter

Publisher

Wiley-Blackwell

Topic

  • Clinical Medicine

Keywords

  • Type 1 diabetes
  • autoimmune diabetes
  • insulin-dependent diabetes
  • Islet autoimmunity
  • Islet autoantibodies
  • HLA genes
  • pathogenesis.

Status

Published

Research group

  • Diabetes and Celiac Unit
  • Paediatric Endocrinology

ISBN/ISSN/Other

  • ISBN: 9781405191814